Opinion|Videos|April 18, 2025
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.
Advertisement
Video content above is prompted by the following:
- Briefly outline the evolving role of PSMA PET imaging in assessing for posttreatment response and how you incorporate it in your practice.
- What is your timing protocol for postradiation PSMA PET imaging?
- Do you routinely use PSMA PET for posttreatment response assessment?
- What value may PSMA-PET posttreatment imaging offer compared with PSA monitoring alone?
- What do available data demonstrate, and how do these findings inform your decisions in this setting?
- 18F PSMA-1007 PET/CT vs PSA (Kleiburg et al. Eur J Rad. 2024)
- 68GaPSMA-11 (Esen et al. J Clin Oncol. 2023.)
- 68Ga-PSMA or 18F-DCFPyL-PSMA (Sutera et al. Adv Rad Onc. 2024)
Advertisement
Related to this article
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5